13F HOLDINGS REPORT
SymBiosis Capital Partners, LLC
Quarter ended Q4 2025 · Filed February 12, 2026 · Accession 0002006045-26-000002
Total Value
$109.5M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Evommune, Inc. | EVMN | 1,280,778 | $21.9M | 20.03% |
| 2 | Verastem Inc | VSTM | 2,000,000 | $15.4M | 14.10% |
| 3 | Aldeyra Therapeutics Inc | AMPGZ | 2,555,000 | $13.2M | 12.09% |
| 4 | Precigen Inc | PGEN | 3,000,000 | $12.5M | 11.45% |
| 5 | Inventiva S.A. | IVEVF | 2,600,000 | $12.1M | 11.04% |
| 6 | Nuvation Bio Inc | NUVB | 1,250,000 | $11.2M | 10.23% |
| 7 | Rani Therapeutics Holdings, Inc. | RANI | 6,300,000 | $8.5M | 7.77% |
| 8 | Aardvark Therapeutics, Inc. | AARD | 476,595 | $6.3M | 5.71% |
| 9 | Clene Nanomedicine Inc. | CLNN | 770,495 | $4.5M | 4.13% |
| 10 | Generation Bio Co | 37148K209 | 665,000 | $3.8M | 3.45% |
| 11 | Surrozen, Inc. | SRZNW | 150,000 | $3,000 | 0.00% |